Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VASC's Cash to Debt is ranked higher than
96% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. VASC: No Debt )
VASC' s 10-Year Cash to Debt Range
Min: 1.11   Max: No Debt
Current: No Debt

Equity to Asset 0.88
VASC's Equity to Asset is ranked higher than
93% of the 450 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. VASC: 0.88 )
VASC' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.96
Current: 0.88

0.34
0.96
Interest Coverage 1238.23
VASC's Interest Coverage is ranked higher than
95% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 234.31 vs. VASC: 1238.23 )
VASC' s 10-Year Interest Coverage Range
Min: 48.63   Max: 9999.99
Current: 1238.23

48.63
9999.99
F-Score: 5
Z-Score: 20.77
M-Score: -2.78
WACC vs ROIC
7.13%
18.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.91
VASC's Operating margin (%) is ranked higher than
90% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. VASC: 15.91 )
VASC' s 10-Year Operating margin (%) Range
Min: -1096.15   Max: 17.33
Current: 15.91

-1096.15
17.33
Net-margin (%) 9.96
VASC's Net-margin (%) is ranked higher than
85% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. VASC: 9.96 )
VASC' s 10-Year Net-margin (%) Range
Min: -1040.69   Max: 27.25
Current: 9.96

-1040.69
27.25
ROE (%) 12.15
VASC's ROE (%) is ranked higher than
87% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 5.02 vs. VASC: 12.15 )
VASC' s 10-Year ROE (%) Range
Min: -72.4   Max: 72.44
Current: 12.15

-72.4
72.44
ROA (%) 10.74
VASC's ROA (%) is ranked higher than
92% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. VASC: 10.74 )
VASC' s 10-Year ROA (%) Range
Min: -67.48   Max: 42.87
Current: 10.74

-67.48
42.87
ROC (Joel Greenblatt) (%) 44.25
VASC's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. VASC: 44.25 )
VASC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2404.09   Max: 56.56
Current: 44.25

-2404.09
56.56
Revenue Growth (3Y)(%) 12.10
VASC's Revenue Growth (3Y)(%) is ranked higher than
86% of the 344 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. VASC: 12.10 )
VASC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.5   Max: 91.3
Current: 12.1

8.5
91.3
EBITDA Growth (3Y)(%) 9.60
VASC's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. VASC: 9.60 )
VASC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.2   Max: 207.2
Current: 9.6

-65.2
207.2
EPS Growth (3Y)(%) -19.80
VASC's EPS Growth (3Y)(%) is ranked higher than
81% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. VASC: -19.80 )
VASC' s 10-Year EPS Growth (3Y)(%) Range
Min: -67.2   Max: 22.1
Current: -19.8

-67.2
22.1
» VASC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VASC Guru Trades in Q1 2014

Joel Greenblatt 24,570 sh (New)
Chuck Royce 141,245 sh (+171.63%)
Bill Frels 134,821 sh (+13.66%)
Jim Simons 302,300 sh (+11.51%)
Mario Gabelli 284,071 sh (-5.68%)
» More
Q2 2014

VASC Guru Trades in Q2 2014

Jim Simons 386,706 sh (+27.92%)
Bill Frels 164,121 sh (+21.73%)
Chuck Royce 171,400 sh (+21.35%)
Mario Gabelli 266,771 sh (-6.09%)
Joel Greenblatt 19,877 sh (-19.1%)
» More
Q3 2014

VASC Guru Trades in Q3 2014

Chuck Royce 171,400 sh (unchged)
Mario Gabelli 266,771 sh (unchged)
Joel Greenblatt Sold Out
Bill Frels 161,170 sh (-1.8%)
Jim Simons 352,000 sh (-8.97%)
» More
Q4 2014

VASC Guru Trades in Q4 2014

Joel Greenblatt 8,442 sh (New)
Chuck Royce 190,300 sh (+11.03%)
Jim Simons 387,300 sh (+10.03%)
Bill Frels 156,073 sh (-3.16%)
Mario Gabelli 255,371 sh (-4.27%)
» More
» Details

Insider Trades

Latest Guru Trades with VASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 New Buy$23.74 - $30.54 $ 29.59%8442
Joel Greenblatt 2014-09-30 Sold Out 0.01%$21.87 - $25.07 $ 29.524%0
Joel Greenblatt 2014-03-31 New Buy0.01%$22.99 - $26.92 $ 29.519%24570
Joel Greenblatt 2013-03-31 Sold Out 0.01%$14.4 - $16.71 $ 29.590%0
Joel Greenblatt 2012-12-31 New Buy0.01%$13.32 - $15.35 $ 29.5102%10137
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 42.50
VASC's P/E(ttm) is ranked higher than
81% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 120.60 vs. VASC: 42.50 )
VASC' s 10-Year P/E(ttm) Range
Min: 5.15   Max: 688.46
Current: 42.5

5.15
688.46
Forward P/E 26.95
VASC's Forward P/E is ranked higher than
86% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 26.95 )
N/A
PE(NRI) 42.30
VASC's PE(NRI) is ranked higher than
81% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 94.20 vs. VASC: 42.30 )
VASC' s 10-Year PE(NRI) Range
Min: 5.14   Max: 895
Current: 42.3

5.14
895
P/B 4.70
VASC's P/B is ranked higher than
69% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. VASC: 4.70 )
VASC' s 10-Year P/B Range
Min: 2.37   Max: 17.18
Current: 4.7

2.37
17.18
P/S 4.30
VASC's P/S is ranked higher than
69% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 3.75 vs. VASC: 4.30 )
VASC' s 10-Year P/S Range
Min: 1.37   Max: 12.36
Current: 4.3

1.37
12.36
PFCF 33.40
VASC's PFCF is ranked higher than
81% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 33.40 )
VASC' s 10-Year PFCF Range
Min: 10.72   Max: 53.46
Current: 33.4

10.72
53.46
POCF 25.60
VASC's POCF is ranked higher than
79% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 74.13 vs. VASC: 25.60 )
VASC' s 10-Year POCF Range
Min: 9.16   Max: 33.43
Current: 25.6

9.16
33.43
EV-to-EBIT 24.06
VASC's EV-to-EBIT is ranked higher than
83% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 68.02 vs. VASC: 24.06 )
VASC' s 10-Year EV-to-EBIT Range
Min: -485.1   Max: 387
Current: 24.06

-485.1
387
PEG 1.36
VASC's PEG is ranked higher than
94% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 1.36 )
VASC' s 10-Year PEG Range
Min: 0.45   Max: 2.98
Current: 1.36

0.45
2.98
Shiller P/E 34.00
VASC's Shiller P/E is ranked higher than
88% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 34.00 )
VASC' s 10-Year Shiller P/E Range
Min: 19.15   Max: 149.17
Current: 34

19.15
149.17
Current Ratio 5.89
VASC's Current Ratio is ranked higher than
89% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. VASC: 5.89 )
VASC' s 10-Year Current Ratio Range
Min: 1.94   Max: 26.32
Current: 5.89

1.94
26.32
Quick Ratio 4.78
VASC's Quick Ratio is ranked higher than
88% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. VASC: 4.78 )
VASC' s 10-Year Quick Ratio Range
Min: 1.36   Max: 25.52
Current: 4.78

1.36
25.52
Days Inventory 136.48
VASC's Days Inventory is ranked higher than
75% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 157.38 vs. VASC: 136.48 )
VASC' s 10-Year Days Inventory Range
Min: 139.78   Max: 240.65
Current: 136.48

139.78
240.65
Days Sales Outstanding 48.31
VASC's Days Sales Outstanding is ranked higher than
89% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 78.80 vs. VASC: 48.31 )
VASC' s 10-Year Days Sales Outstanding Range
Min: 38.82   Max: 116.17
Current: 48.31

38.82
116.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.20
VASC's Price/Net Cash is ranked higher than
88% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 19.20 )
VASC' s 10-Year Price/Net Cash Range
Min: 0.59   Max: 539.5
Current: 19.2

0.59
539.5
Price/Net Current Asset Value 10.90
VASC's Price/Net Current Asset Value is ranked higher than
86% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 10.90 )
VASC' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 38.24
Current: 10.9

0.54
38.24
Price/Tangible Book 5.80
VASC's Price/Tangible Book is ranked higher than
75% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 6.96 vs. VASC: 5.80 )
VASC' s 10-Year Price/Tangible Book Range
Min: 0.68   Max: 10.77
Current: 5.8

0.68
10.77
Price/DCF (Projected) 2.10
VASC's Price/DCF (Projected) is ranked higher than
88% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 2.10 )
VASC' s 10-Year Price/DCF (Projected) Range
Min: 1.34   Max: 130.33
Current: 2.1

1.34
130.33
Price/Median PS Value 1.60
VASC's Price/Median PS Value is ranked higher than
67% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. VASC: 1.60 )
VASC' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 12.58
Current: 1.6

0.3
12.58
Price/Peter Lynch Fair Value 2.90
VASC's Price/Peter Lynch Fair Value is ranked higher than
95% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 2.90 )
VASC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.23   Max: 8.67
Current: 2.9

0.23
8.67
Price/Graham Number 3.30
VASC's Price/Graham Number is ranked higher than
84% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. VASC: 3.30 )
VASC' s 10-Year Price/Graham Number Range
Min: 0.89   Max: 10.83
Current: 3.3

0.89
10.83
Earnings Yield (Greenblatt) 4.10
VASC's Earnings Yield (Greenblatt) is ranked higher than
83% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. VASC: 4.10 )
VASC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 10.3
Current: 4.1

0.3
10.3
Forward Rate of Return (Yacktman) 16.95
VASC's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 5.08 vs. VASC: 16.95 )
VASC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -57.3   Max: 54.1
Current: 16.95

-57.3
54.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:VA4.Germany,
Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Companys products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Companys products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for VASC

Headlines

Articles On GuruFocus.com
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 01 2011 
Vascular Solutions Inc. (VASC) CEO Howard Root sells 25,000 Shares Nov 04 2010 
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 02 2010 
Vascular Solutions Inc. Reports Operating Results (10-Q) Apr 17 2009 
Vascular Solutions, Inc. to Webcast Fourth Quarter Conference Call Tuesday, February 3, 2009 at 3:30 Jan 08 2009 


More From Other Websites
Walgreens Boots: Market Optimism on Merger Makes It a Buy - Analyst Blog Feb 26 2015
Medtronic's VenaSeal Wins FDA Nod for Vericose Veins Cure - Analyst Blog Feb 26 2015
Are You Considering Abaxis (ABAX) Post Solid Q3 Earnings? - Analyst Blog Feb 25 2015
Medtronic Adds Advanced Uro-Solutions to Neuromodulation - Analyst Blog Feb 24 2015
ResMed Upped to Hold on Several Growth Initiatives - Analyst Blog Feb 24 2015
Medtronic's Artificial Pancreas Technology: Key to Diabetes Cure? - Analyst Blog Feb 23 2015
Zimmer Upbeat on Biomet Takeover, Americas Sales Disappoint - Analyst Blog Feb 23 2015
Hanger to Amend and Reissue Financial Data; Results Delayed - Analyst Blog Feb 18 2015
Medtronic Hits 52-Week High on Solid Q3, Portfolio Strength - Analyst Blog Feb 18 2015
Owens & Minor Lags Q4 Earnings Estimates, Revenues Beat - Analyst Blog Feb 18 2015
Vascular Solutions Set to Join the S&P SmallCap 600 Feb 17 2015
Medtronic's Spinal System Wins FDA Nod for Expanded Use - Analyst Blog Feb 17 2015
Medtronic's Euphora Balloon Catheter Family Expands in UK - Analyst Blog Feb 17 2015
Medtronic Tops Q3 Earnings, Revenues; Offers Joint Q4 View - Analyst Blog Feb 17 2015
CareFusion to Distribute Breas Medical's Vivo Ventilators in US - Analyst Blog Feb 10 2015
VASCULAR SOLUTIONS INC Financials Feb 10 2015
10-K for Vascular Solutions, Inc. Feb 05 2015
Vascular Solutions posts 4Q profit Feb 03 2015
Vascular Solutions posts 4Q profit Feb 03 2015
VASCULAR SOLUTIONS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK